Osteoporosis in Chronic Obstructive Pulmonary Disease: More than just a Comorbidity
Abstract
Chronic Obstructive Pulmonary Disease (COPD) is one of the leading causes of mortality and loss of Disability-Adjusted Life-Years (DALYs) worldwide. It often is accompanied by the presence of various systemic comorbidities including osteoporosis which may have an impact on the course of the disease. Osteopenia and osteoporosis are the consequences of loss of Bone Mineral Density (BMD) and have been widely known major comorbidities in COPD patients.
Female sex, age, and smoking are common pathogenic factors for both COPD and osteoporosis, other factors such as reduced daily physical activity, malnutrition, low body mass index, hypogonadism, vitamin D deficiency, chronic renal insufficiency, chronic hypoxemia, and drugs like corticosteroids, have been invoked to explain such a frequent association between them. Osteoporosis in COPD is however often undertreated. It has been shown in recent studies that both decreased Bone Mineral Density (BMD) and impaired bone quality contribute to bone fragility, causing fractures in COPD patients. Pulmonary function and activities of the daily life of COPD patients may be further deteriorated by osteoporosis-associated fractures. Calcium and vitamin D, hormone replacement when indicated, calcitonin, and bisphosphonate administration are few effective strategies to tackle bone loss and osteoporosis. Awareness about this high prevalence of osteoporosis in COPD patients is critically important and physicians should look for such fracture risks. Routine screening and early diagnosis of osteoporosis will enable physicians to provide the appropriate treatment to prevent fracture, which leads to improved quality of life as well as better long-term prognosis.
How to cite this article:
Daga MK, Kumar N, Raghu RV, Mawari G, Chand S, Aarthi J. Osteoporosis in Chronic Obstructive Pulmonary Disease: More than just a Comorbidity. J Adv Res Med 2020; 7(3): 7-12.
DOI: https://doi.org/10.24321/2349.7181.202011
References
Gan WQ, Man SFP, Senthilselvan A et al. Association between chronic obstructive pulmonary disease and
systemic inflammation: a systematic review and a meta analysis. Thorax 2004; 59: 574e80.
Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A
multiple cause coding analysis. Eur Respir J 2003; 22: 809-814.
Mannino DM, Watt G, Hole D et al. The natural history of chronic obstructive pulmonary disease. Eur Respir
J 2006; 27: 627-643.
Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD)
classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC)
study. Respir Med 2006; 100: 115-122.
Graat-Verboom L, Wouters EFM, Smeenk FW, et al. Current status of research on osteoporosis COPD: a
systematic review. Eur Respir J 2009; 34: 209-218.
Cavailles A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert C, Marchand-Adam S et al. Comorbidities
of COPD. Eur Respir Rev 2013; 22(130): 454-475.
Scanlon PD, Connett JE, Wise RA et al. Loss of bone density with inhaled triamcinolone in Lung Health Study
II. Am J Respir Crit Care Med 2004; 170: 1302-1309.
Ferguson GT, Calverley PMA, Anderson JA et al. Prevalence and progression of osteoporosis in patients
with COPD. Results from the towards a revolution in COPD Health Study. Chest 2009; 136: 1456-1465.
Mineo TC, Ambrogi V, Mineo D et al. Bone mineral density improvement after lung volume reduction
surgery for severe emphysema. Chest 2005; 127: 1960-1966.
Maggi S, Siviero P, Gonnelli S et al. EOLO Study Group. Osteoporosis risk in patients with chronic obstructive
pulmonary disease: the EOLO study. J Clin Densitom 2009; 12: 345–352.
Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med 2010; 7: e1000220.
Janssens W, Bouillon R, Claes B et al. Vitamin D deficiency is highly prevalent in COPD and correlates
with variants in the vitamin D-binding gene. Thorax 2010; 65: 215-220.
Balasubramanian, Vijaya; Naing, Soeb Hypogonadism in chronic obstructive pulmonary disease: incidence
and effects, Current Opinion in Pulmonary Medicine: March 2012 - Volume 18 - Issue 2 - p 112-117 doi:
1097/MCP.0b013e32834feb37.
Leech JA, Dulberg C, Kellie S et al. Relationship of lung function to severity of osteoporosis in women. Am Rev
Respir Dis 1990; 141: 68-71.
Lisboa C, Moreno R, Fava M et al. Inspiratory muscle function in patients with severe kyphoscoliosis. Am
Rev Respir Dis 1985; 132: 48-52.
Myers AH, Robinson EG, Van Natta ML et al. Hip fractures among the elderly: factors associated with
in-hospital mortality. Am J Epidemiol 1991; 134: 1128-1137.
Shane E, Silverberg SJ, Donovan D et al. Osteoporosis in lung transplantation candidates with end-stage
pulmonary disease. Am J Med 1996; 101: 262-269.
McEvoy C, Ensrud K, Bender E et al. Association between corticosteroid use and vertebral fractures in
older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 704-709.
Lyles KW, Gold DT, Shipp KM et al. Association of osteoporotic vertebral compression fractures with
impaired functional status. Am J Med 1993; 94: 595-601.
Nevitt MC, Ettinger B, Black DM et al. The association of radiographically detected vertebral fractures with
back pain and function: a prospective study. Ann Intern Med 1998; 128: 793-800.
Culham EG, Jimenez HA, King CE. Thoracic kyphosis, rib mobility, and lung volumes in normal women and
women with osteoporosis. Spine 1994; 19: 1250-1255.
Mussolino ME, Looker AC, Madans JH et al. Risk factors for hip fracture in white men: the NHANES I
epidemiologic follow-up study. J Bone Miner Res 1998; 13: 918-924.
Van Staa TP, Leufkens HGM, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J Bone Miner
Res 2000; 15: 993-1000.
Cooper C, Melton LJ. Magnitude and impact of osteoporosis and fractures. In: Marcus R, Feldman D,
Kelsey J, eds. Osteoporosis. New York, NY: Academic Press, 1995; 419-434.
NIH Consensus Development Panel on Osteoporosis Prevention D, and Therapy. Osteoporosis prevention,
diagnosis, and therapy. JAMA 2001; 285(6): 785-795.
Mk D, Bk G, G M, Hs H, T S, D B. Assessment of Osteoporosis and Osteopenia and its Co-Relation with
Disease Severity in Patients of Chronic Obstructive Pulmonary Disease with Respect to Associated Risk
Factors: A Case Control Study in India. J Pulm RespirMed [Internet] 2018; [cited 2020 Sep 13]; 08(02).
2019 International Society of Clinical Densitometry Official Positions – Adult. Available from: https://www.
iscd.org/official-positions/2019-iscd-official-positionsadult/.Accessed on 11th October, 2020.
Elaine W Yu.Screening for osteoporosis. Available from https://www.uptodate.com/contents/screening-forosteoporosis#H14. Accessed on 11th October, 2020.
Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929-36.
National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. 2008.
http://www.nof.org/professionals/cliniciansguide_form.asp. Accessed 2009 Oct 22.
Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S, Lindsay RL; National Osteoporosis
Foundation Guide Committee. Implications of absolute fracture risk assessment for osteoporosis practice
guidelines in the USA. Osteoporos Int 2008; 19: 449-58.
Unnanuntana A, Gladnick BP, Donnelly E, Lane JM. The Assessment of Fracture Risk. J Bone Jt Surg-Am
; 92(3): 743-53.
Kanis JA, Oden A, Johnell O et al. The use of clinical risk factors enhances the performance of BMD in the
prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007; 18: 1033-46.
Avenell A, Gillespie WJ, Gillespie LD et al. Vitamin D and vitamin D analogs for preventing fractures associated
with involutional and post-menopausal osteoporosis.Cochrane Database Syst Rev 2009; 2: CD000227.
Buckley LM, Leib ES, Cartularo KS et al. Calcium and vitamin D3 supplementation prevents bone loss in
the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: a randomized,
double-blind, placebo-controlled trial. Ann Intern Med 1996; 125: 961-968.
Garcia-Delgado I, Prieto S, Gil-Fraguas L et al. Calcitonin, etidronate, and calcidiol treatment in bone loss after
cardiac transplantation. Calcif Tissue Int 1997; 60: 155-159.
Smith BJ, Laslett LL, Pile KD et al. Randomized controlled trial of alendronate in airways disease and low bone
mineral density. Chron Respir Dis 2004; 1: 131-137.
Grossman JM, Gordon R, Ranganath VK et al. American College of Rheumatology 2010 recommendations for
the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62:
-1526.
Chen LX, Zhou ZR, Li YL et al. Comparison of bone mineral density in lumbar spine and fracture rate
among eight drugs in treatments of osteoporosis in men: a network meta-analysis. PLoS One 2015; 10(5):
e0128032.
Luengo M, del Rio L, Pons F et al. Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study. Eur Respir J 1997; 10: 2110-2113.
